Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (Glycotargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.